CN111202722A - Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof - Google Patents
Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN111202722A CN111202722A CN202010090402.0A CN202010090402A CN111202722A CN 111202722 A CN111202722 A CN 111202722A CN 202010090402 A CN202010090402 A CN 202010090402A CN 111202722 A CN111202722 A CN 111202722A
- Authority
- CN
- China
- Prior art keywords
- lopinavir
- dry powder
- particles
- inhalation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 title claims abstract description 45
- 229960004525 lopinavir Drugs 0.000 title claims abstract description 45
- 239000000843 powder Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 238000010008 shearing Methods 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 83
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 238000001694 spray drying Methods 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000012752 auxiliary agent Substances 0.000 claims description 7
- 229960001375 lactose Drugs 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- -1 sugar alcohol compounds Chemical class 0.000 claims description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 229960001021 lactose monohydrate Drugs 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 206010035737 Pneumonia viral Diseases 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 208000009421 viral pneumonia Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241001466953 Echovirus Species 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 238000000975 co-precipitation Methods 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000009474 hot melt extrusion Methods 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 15
- 239000008187 granular material Substances 0.000 description 16
- 239000007921 spray Substances 0.000 description 11
- 210000002345 respiratory system Anatomy 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 229960000311 ritonavir Drugs 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 241000701370 Plasmavirus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 231100000037 inhalation toxicity test Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 description 1
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108010055591 SARS coronavirus 3C-like protease Proteins 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of medicines, and discloses a lopinavir inhalation dry powder pharmaceutical composition, a preparation method and a medical application thereof. The dry powder medicine composition contains lopinavir as an active ingredient and pharmaceutically acceptable auxiliary materials, and is formed by shearing and mixing, and targeted lung administration can be realized through a dry powder inhalation device.
Description
Technical Field
The invention belongs to the technical field of medicinal preparations, and particularly relates to a preparation method of an inhalation dry powder medicinal composition.
Background
Aiming at 2019-nCoV, no specific antiviral drug exists at present all over the world, the specific antiviral drug is mainly used for symptomatic treatment of symptoms of patients, no effective antiviral drug exists, and a proper antiviral drug needs to be quickly found according to the current epidemic situation, so that the medicine has important significance for treating infectors, controlling epidemic spread and reducing fatality rate at a reasonable medicine application time.
2019-nCoV virus and SARS coronavirus have similar receptor binding path, and through the molecular mechanism of the binding interaction of S-protein and human ACE2 receptor, ACE2 exists in pulmonary alveoli and small intestine epithelial cells, and is expressed on the surfaces of arteriovenous epithelial cells and arterial smooth muscle cells of all organs, wherein the respiratory tract epithelial cells are distributed most, so that the respiratory tract and the lung are most susceptible to infection.
2019-nCoV virus can be detected in the excrement of severe patients, and no virus is detected in the urine, which indicates that the virus is gathered in alveoli after invading from respiratory tract and exists in large amount in digestive tract at later stage. However, the literature reports that the serum detection of 2019-nCoV of the American patient is negative, the detection result of the plasma of the 2019-nCoV of the Wuhan patient in China is corresponding to the detection result, the positive rate is only (6/41) 15%, and compared with the detection rate of SARS-CoV plasma virus being 79%, the detection rate of the SARS-CoV plasma virus is 79%, so that the antiviral drug for treating SARS-CoV can be absorbed into the blood from the gastrointestinal tract after oral administration, and the 2019-nCoV virus with very low concentration in the blood can not be killed.
By analyzing the symptoms of patients, the symptoms of upper respiratory tract such as nasal obstruction, nasal discharge, sore throat and the like are not obvious, and the 2019-nCoV virus of the upper respiratory tract (including nasopharynx part and oropharynx part) of most patients is negative in detection, and the 2019-nCoV virus can be detected only by collecting alveolar lavage fluid, which shows that the virus has extremely high affinity to lung, so that the medicine needs to directly reach a target point, namely alveolus.
Oral absorption of Ritonavir (Ritonavir) is effective in inhibiting aspartic protease, blocking the enzymatic activity of the polypeptide required to produce morphologically mature HIV granules, thereby maintaining the HIV granules in an immature state and inhibiting cytochrome P450 enzymes CYP3A and CYP2D 6. The common adverse reactions include fatigue, gastrointestinal symptoms, nerve dysfunction and the like. Lopinavir is SARS-CoV main protease activity MproAlso in the low micromolar range, MERS-CoV activity. And clinical studies show thatLopinavir-ritonavir treatment reduced mortality from MERS-CoV marmosets. In the ' diagnosis and treatment of SARS ' infection ' it is explicitly mentioned that in the course of antiviral therapy the protease inhibitor-type medicaments such as lopinavir/ritonavir can be used.
A lopinavir/ritonavir combination formulation approved for sale, developed by AbbVie (AbbVie), under the trade name: the gram-force ganoderma lucidum has two dosage forms of tablets and oral liquid, is administrated by an oral route, is less distributed at key focus positions such as respiratory tract, lung and the like, and causes the slow effect of the medicine. Lopinavir inhalant has the possibility of being the first small-molecule compound inhalant for treating coronavirus, and the inhalant has the following advantages: the ritonavir is clinically effective, in an oral compound preparation, the ritonavir is used as a reinforcing agent of the lopinavir, so that the condition that the blood concentration is too low and the treatment effect is lost due to too fast metabolism of the lopinavir is avoided; the lopinavir inhalant directly acts on the lung, targeted administration is carried out on the lung, the lopinavir inhalant directly reaches the focus, and the lung has large absorption surface area, rich capillary vascular network and thin alveolar epithelial cell layer, so that the substance exchange distance is short, the speed is high, and the effect of quick response is achieved; the preparation targets the focus, has accurate dosage and quick response, can quickly improve the pulmonary infection condition, and is beneficial to improving the adaptability of infected people; the targeted drug delivery avoids the absorption through the gastrointestinal tract and reduces the side effect of the gastrointestinal tract.
The Pulmonary Drug Delivery System (PDDS) refers to a drug delivery system in which a drug is delivered directly into the respiratory tract via a special drug delivery device to perform local or systemic therapeutic action. Current pulmonary delivery systems include Metered Dose Inhalation (MDI), inhalation spray (inhalation), Dry Powder Inhalation (DPI), and Dry Powder Inhaler (DPI). Wherein, the aerosol needs a propellant, can destroy the atmospheric ozone layer, and requires the synergistic action of patients when in use. The spraying device of the spraying agent is too large, inconvenient to carry, low in efficiency, poor in repeatability, large in individual difference and long in inhalation process. Compared with aerosol and spray, the dry powder inhalation has no requirement of synergistic effect, does not need a propellant, has larger delivery dose and is more suitable for macromolecular drugs.
The dry powder inhalant is a new dosage form developed on the basis of quantitative inhalation aerosol and by integrating the knowledge of powder engineering, and is a drug delivery system which disperses micronized drugs alone or after being sheared and mixed with a carrier into mist to enter respiratory tracts through the active inhalation of patients by a special drug delivery device and plays a local or systemic role.
The physiological structure of the lung requires that the drug particles of the dry powder inhalant are very fine, generally, the ideal drug particle size is 1-5 μm, particles larger than the range can not enter the bronchioles, and smaller particles are easy to breathe and exhale. The drug carrier is mainly used for adsorbing drug particles, enhancing the stability of the drug during storage and keeping the drug in an amorphous glass state. When the patient inhales, the shear forces created by the turbulent air flow separate the drug from the carrier, with particles smaller than 5 μm entering the lower respiratory tract, and large particles of carrier or drug falling into the mouth and throat. The greater the shear force generated by the air turbulence, the higher the proportion of particulate drug successfully separated from the carrier, and the higher the lung deposition rate.
Lopinavir (Lopinavir) is easily soluble in methanol and ethanol, soluble in isopropanol, hardly soluble in water, poor in water solubility, better in lipid solubility, high in first pass effect and extremely poor in systemic bioavailability, but the Lopinavir is high in lung affinity and quick in inactivation effect, and is clinically suitable for being developed into a pulmonary inhalation preparation for treating pulmonary virus infection, wherein the Lopinavir is mentioned in the Rapid suggestion (standard version) for diagnosis and treatment of pneumonia infected by novel coronavirus (2019-nCoV), (1) a medicament for treating suspected or confirmed cases of specific anti-novel coronavirus in which no evidence from RCT exists at present, (2) the Lopinavir/ritonavir is taken as an oral administration dosage, 2 tablets/time and 2 times/day, the daily administration dosage recommended by the Lopinavir is 800mg according to the suggestion, the dosage conditions are particularly low in self-solubility and large in side effect, become a bottleneck of other administration technologies, particularly colloidal state of Lopinavir is developed, the Lopinavir is a dry injection preparation containing no povidone-inhalation active ingredient, particularly no povidone-vitamin A vitamin E is mentioned in a hot-melt inhalation test method, and a dry inhalation test method is adopted, wherein no povidone-vitamin A is mentioned in the dry injection test, no more suitable for improving bioavailability experiment, no toxic and no toxicity test is mentioned in the dry injection by the dry injection method of Lopinavir, no toxicity test of Lopinavir, No. 1000.
The invention adopts the spray drying method to prepare the amorphous lopinavir, greatly increases the solubility and the bioavailability, reduces the administration dosage, simultaneously considers adding the dispersing auxiliary agent into the spray drying solution, improves the physicochemical property and the inhalation performance of the medicine particles, and is convenient to be uniformly mixed with an external carrier.
Disclosure of Invention
In order to overcome the disadvantages of the prior art, the present invention provides a novel dry powder pharmaceutical composition for inhalation comprising lopinavir, a dispersion aid and a pharmaceutically acceptable carrier, which can be administered to the lung via a dry powder inhalation device, and a method for preparing the same.
The active ingredient is lopinavir, is used for treating viral diseases, is amorphous, and accounts for 5-50% of the total weight of the composition, preferably 10-30%.
The medicinal auxiliary materials in the dry powder inhalant comprise a dispersing auxiliary agent and a large-particle-size carrier according to functional division.
The dispersing auxiliary agent can make the granules have proper dispersity, and can prevent the granules from agglomerating and adhering, and is selected from one or more of sugar and sugar alcohol compounds, including but not limited to lactose, mannitol, sorbitol and the like, preferably mannitol.
The dispersibility aid is small molecular amino acids, and can be one or more selected from alanine, valine, leucine, isoleucine and phenylalanine, preferably leucine.
The large particle size carrier serves to aid in the transport of the drug particles from the site of administration to the throat. Lopinavir dry powder inhalants are suitable for delivery from the throat area to the lungs through the respiratory tract when the particles are small in size and highly dispersible, but are not suitable for delivery from the administration site to the throat area, and it is desirable to add a carrier of large particle size.
The carrier with large particle size is selected from one or more of saccharides and sugar alcohols, preferably one or more of lactose, mannitol, trehalose, sucrose, sorbitol, glucose, β -cyclodextrin, dimethyl β -cyclodextrin, erythritol and the like, and preferably one or more of lactose monohydrate or lactose.
The carrier with large particle size is characterized in that the particle size of more than 50 percent of particles is 25-300 mu m, preferably the particle size of more than 70 percent of particles is 50-200 mu m, and more preferably the particle size of more than 90 percent of particles is 50-100 mu m. The mixing ratio of the drug particles and the large-particle-size carrier is 100: 1-1: 100, preferably 50: 1-1: 50, and more preferably 20: 1-1: 20 by weight.
It is another object of the present invention to provide a process for the preparation of a dry powder pharmaceutical composition for inhalation comprising the steps of:
(a) dissolving lopinavir serving as a medicinal active ingredient and a dispersing auxiliary agent into an organic solvent, and performing spray drying to prepare amorphous medicinal granules;
(b) shearing and mixing the drug particles obtained in the step (a) and the large-particle-size carrier to obtain the drug.
The amorphous lopinavir particles have the particle size of more than 50 percent of particles between 0.1 and 10 mu m, preferably more than 70 percent of particles between 1 and 5 mu m, and more preferably more than 90 percent of particles between 2 and 4 mu m. Typically, the particle size of a particle is determined quantitatively by measuring the characteristic equivalent sphere diameter (referred to as the volume diameter) by laser diffraction, for example by a laser particle size tester.
The amorphous lopinavir particles can be prepared by one or more of spray drying, hot-melt extrusion, grinding method, coprecipitation method and the like, and the spray drying method is preferred. When the lopinavir particles are prepared by adopting a spray drying method, a solution for spray drying is firstly prepared, namely, the active ingredients and the dispersing auxiliary are respectively dissolved and then combined or uniformly dissolved into a solution state, and then the solution is used for subsequent spray drying. According to the lopinavir dissolution characteristics, the solvent is selected from ethanol, methanol, propylene glycol or an aqueous solution thereof, preferably an aqueous ethanol solution, more preferably a 50% ethanol solution.
The solids content of the solution for spray drying affects the efficiency of spray drying and the particle size and properties of the spray-dried particles and should generally be between 0.5 and 10% (w/v), preferably between 1 and 5% (w/v), more preferably between 1 and 3% (w/v).
In spray drying, the main process parameters that affect the performance of the produced particles include the spray drying gas inlet temperature, the spray gas flow rate, the spray liquid flow rate, and the like. The higher the inlet temperature of the spray drying gas is, the faster the drying speed is, the higher the material processing capacity is, but the more easily the main drug and the pharmaceutical excipients are chemically degraded/reacted, so the suitable inlet temperature is 80-140 ℃, preferably 90-130 ℃, and more preferably 100-120 ℃.
The higher the spray gas flow is, the faster the drying speed is, the higher the material processing capacity is, but the higher the power consumption is, the more easily the main medicine and the pharmaceutic adjuvant are subjected to chemical degradation/reaction, so that the suitable gas flow is 0.2-1.0 m3Min, preferably 0.3-0.8 m3Min, and more preferably 0.5 to 0.7 m3/min。
The lower the liquid spraying flow is, the higher the gas-liquid flow ratio is, the faster the drying speed is, the smaller the particle size of the obtained particles is, but the treatment amount can be obviously reduced, the treatment time can be obviously prolonged, and the longer the treatment time is, the more easily the main drug and the pharmaceutic adjuvant are caused to be chemically degraded/reacted, so the suitable liquid spraying flow is 1-10ml/min, preferably 2-8ml/min, and more preferably 5-7 ml/min.
In other spray drying conditions, the type of spray drying gas is not particularly limited, and air may be used, but nitrogen or an inert gas may be selected as the spray drying gas in order to further reduce the chemical reaction.
Because the fluidity of the prepared particles is reduced due to too high moisture content, the stability is poor or/and the particle size of the particles is increased in the storage process, the particles are controlled by the operating parameters in the spray drying process, and it is noted that once the solution is sprayed, the inlet temperature is adjusted to keep the outlet temperature at 70-80 ℃ for about 10-15 min, so that the residual moisture of the obtained particles is further reduced by secondary drying. The water content in the granules is controlled to be 5% or less, preferably 3% or less, more preferably 2% or less.
The shearing mixing of the invention refers to that the particles in the material group are subjected to the external force from a cutter, a stirring paddle or a screen mesh, and the particles mutually form the sliding and collision action of a shearing surface, so that the local mixing is caused. The shear mixing means a device generally used for material dispersion and pulverization, and includes a disk mill, a knife mill, a ball mill, a high-speed mixer, a high-speed pulverizer, etc., preferably a high-speed mixer. The aggregate can be broken up by adopting high-speed shearing and mixing, so that the acting force between the main drug particles and the carrier is greater than that between the main drug particles, and a highly uniform drug composition is obtained, but the particle size distribution and stability of the mixed powder can be influenced by a high-energy shearing and mixing mode, poor sequence, overlong time and the like, so that all influencing factors are comprehensively considered, and a proper and time-saving shearing and mixing process is selected.
The dry powder formulations obtained by the process of the present invention, which are uniformly dispersed, can be administered by dosing in single-dose or multi-dose containers, which can be capsules or blisters, preferably capsules, more preferably HPMC capsules, by appropriate packaging to provide chemical and physical protection, by active or passive inhalation devices. The capsule can be used for inhalation preparation, and also can be used for oral administration.
The invention amorphizes the active ingredient by a spray drying technology, improves the dissolubility and bioavailability and reduces the administration dosage, in order to improve the inhalation characteristic of the particles obtained by spray drying, a dispersing auxiliary agent is added to ensure that the particles with proper particle size distribution have good dispersity and low hygroscopicity, and finally, the particles and a carrier with large particle size are sheared and mixed, thereby providing a preparation method of the dry powder pharmaceutical composition for inhalation. The composition can be administered to lung by dry powder inhalation device, has high aerodynamic Fine Particle Fraction (FPF), and has the advantages of good inhalation property, good stability and high safety.
The invention also provides application of the pharmaceutical composition in preparing medicaments for treating viral diseases, wherein the viral diseases comprise viral pneumonia and AIDS, and the viral pneumonia is pneumonia caused by viruses such as influenza virus, parainfluenza virus, cytomegalovirus, adenovirus, rhinovirus, coronavirus, 2019 novel coronavirus, coxsackie, echovirus, herpes simplex, varicella-zoster, rubella, measles and the like.
Detailed Description
Example 1: preparation of amorphous lopinavir
Dissolving lopinavir in 50% ethanol solution with solid content of 3% (w/v), spray drying according to the following process parameters, collecting the obtained particles, and calculating the yield.
Inlet temperature: 120 deg.C
Liquid spraying flow rate: 6ml/min
Atomization pressure: 180KPa
Flow rate of spray gas: 0.6 m3/min。
Example 2: preparation of amorphous lopinavir granules
Weighing lopinavir according to the ratio of 7:2:1 (w/w/w): mannitol: leucine was dissolved in 50% ethanol solution with a solid content of 3% (w/v), spray dried according to the process parameters in example 1 and the resulting particles were collected.
Example 3: preparation of amorphous lopinavir granules
Weighing lopinavir according to the ratio of 7:2:1 (w/w/w): lactose: leucine was dissolved in 50% ethanol solution with a solid content of 3% (w/v), spray dried according to the process parameters in example 1 and the resulting particles were collected.
Example 4: preparation of amorphous lopinavir granules
Weighing lopinavir according to the ratio of 5.5:3:1.5 (w/w): mannitol: leucine was dissolved in 50% ethanol solution with a solid content of 3% (w/v), spray dried according to the process parameters in example 1 and the resulting particles were collected.
Example 5: lopinavir composition preparation for dry powder inhalation using lactose monohydrate as large particle size carrier
Lactose monohydrate was weighed according to the following table and mixed with the granulate of example 4 in a high speed mixer with shear for 10 min.
| Lactose monohydrate | 70.0g |
| Lopinavir granules | 30.0g |
| Total up to | 100.0g |
Drug particle saturation solubility determination
Adding excessive particles in the embodiments 1-4 into purified water, oscillating for 24 hours at the rotating speed of 200 rpm, centrifuging, taking supernate and determining the saturated solubility, wherein the results are as follows:
| raw material for non-treatment | Example 1 | Example 2 | Example 3 | Example 4 | |
| Saturated solubility (mg/ml) | 0.02 | 24.8 | 26.4 | 19.2 | 23.5 |
The lopinavir alone of example 1 had a greatly increased saturated solubility after spray drying compared to the untreated base.
Yield, angle of repose, particle size D90And evaluation of moisture absorption
"particle size (D90)" according to the invention: the laser particle size tester measures the percentage of particles with different particle sizes in the powder sample to the total amount of the particles, and D90 indicates the corresponding particle size when the cumulative particle size distribution percentage of one sample reaches 90%.
The angle of repose of the powder is measured by a fixed funnel method, also known as a residual cone method. Injecting sample powder into the center of a disc with a certain limited diameter through a funnel until the material on the inclined edge of the powder accumulation layer automatically flows out along the edge of the disc, stopping injecting, measuring the height of a cone formed on the disc, and comparing the height with the radius of the disc to obtain the tangent value of the repose angle, thereby obtaining the repose angle. It is considered that the smaller the angle of repose, the smaller the friction force, the better the fluidity, and the easier the filling.
The "hygroscopicity" of the present invention: the method is carried out according to the guideline of the drug hygroscopicity test in the appendix of the second part of Chinese pharmacopoeia 2015 edition.
| Yield (%) | Angle of repose: (。） | D90（μm） | Moisture absorption (%) | |
| Example 1 | 55 | 55.5 | 5.97 | 30.59 |
| Example 2 | 66 | 45.0 | 4.97 | 26.25 |
| Example 3 | 62 | 49.8 | 6.09 | 30.86 |
| Example 4 | 68 | 39.3 | 5.54 | 22.08 |
From the above results, it can be seen that the addition of the dispersion aid increases the yield of the drug granules, decreases the angle of repose, improves the flowability of the granules, and decreases the particle size of the granules, and that, in comparison with examples 2 and 3, smaller angles of repose and particle size were obtained compared with the granules obtained by adding lactose to mannitol, indicating that the granules had better flowability, more uniform particle size distribution, and less hygroscopicity. Comparing examples 2 and 4, the larger the amount of mannitol and leucine used, the smaller the angle of repose and hygroscopicity.
Stability study of the composition
The purpose of this study was to examine the effect of the dry powder composition of example 5 on stability.
The powder of example 5 was filled in capsules at 25 mg/capsule, placed under long-term conditions (25 ℃/RH 60%) and accelerated conditions (40 ℃/75% RH) for 1 month, and then samples were taken to measure the substances concerned, and the content of impurities was counted to determine the tendency of change of impurities.
The "fog particle distribution", namely the fine particle dose (FPF), is an important parameter for evaluating the quality of an inhaled preparation, and refers to the percentage of the fine drug particle dose of the inhaled powder aerosol in a labeled amount, which can be measured by an in vitro device (refer to "0951 inhalation preparation fine particle aerodynamic property measurement method" in the fourth part of the chinese pharmacopoeia 2015), and the numerical value of the "fog particle distribution", which can reflect the deposition rate of an active ingredient in the lung, for example, when the gas flow reaches 60L/min, the ratio of the fog particle distribution in 2-7 grades is equivalent to the deposition rate of the active ingredient in the lung.
The test instrument: the New Generation of Impactors (NGI) are equipment available from COPLEY, united kingdom.
The dry powder mixture of example 5 was loaded in an aliquot of 25mg into HPMC capsule # 3, the spray distribution and emitted dose of the dry powder in each capsule were measured using a New Generation Impactor (NGI) at a flow rate of 60L/min for 4s per inhalation time, and the amount of the 2 nd to 7 th (aerodynamic particle size range: 0.34 to 4.46 μm) collection pan was counted as the total spray distribution.
| At 0 time | Accelerated condition of 1 month | Long term conditions of 1 month | |
| Total impurities (%) | 0.18 | 0.26 | 0.20 |
| FPF value (%) | 42.5 | 45.8 | 46.4 |
Claims (10)
1. A lopinavir inhalation dry powder pharmaceutical composition comprises lopinavir and pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials comprise:
(1) large particle size carrier selected from sugar and sugar alcohol compounds, including but not limited to lactose, mannitol, trehalose, sucrose, sorbitol, glucose, β -cyclodextrin and dimethyl β -cyclodextrin, erythritol and one or more of them, preferably lactose monohydrate or anhydrous lactose;
(2) the dispersing auxiliary agent can be selected from sugar and sugar alcohol compounds, including but not limited to lactose, mannitol, sorbitol and the like, and can also be selected from one or more of small molecular amino acids, alanine, valine, leucine, isoleucine, phenylalanine and the like, and mannitol and leucine are preferred.
2. Composition according to claim 1, characterized in that the active ingredient lopinavir is in amorphous form, representing between 5% and 50% of the total weight of the composition, preferably between 10% and 30%.
3. The pharmaceutical composition of claim 1 or 2, wherein the amorphous lopinavir has a particle size of 0.1 to 10 μm for more than 50%, preferably 1 to 5 μm for more than 70%, and more preferably 2 to 4 μm for more than 90%.
4. A dry powder pharmaceutical composition for inhalation according to claim 3, wherein said large particle size carrier comprises more than 50% of the particles having a size of between 25 and 300 μm, preferably more than 70% of the particles having a size of between 50 and 200 μm, more preferably more than 90% of the particles having a size of between 50 and 100 μm.
5. A process for the preparation of a dry powder pharmaceutical composition for inhalation according to claim 1 comprising the steps of:
(a) dissolving lopinavir and a dispersing auxiliary agent into an organic solvent, and performing spray drying to prepare amorphous drug particles;
(b) shearing and mixing the drug particles obtained in the step (a) and the large-particle-size carrier to obtain the drug.
6. The preparation method of claim 5, wherein the amorphous lopinavir is prepared by one or more of spray drying, hot-melt extrusion, milling, and coprecipitation, preferably spray drying.
7. The process according to claim 5 or 6, characterized in that the organic solvent is selected from ethanol, methanol, propylene glycol, and the like or aqueous solutions thereof, preferably aqueous ethanol solution; the solid content of the solution is 0.5-10% (w/v), preferably 1-5% (w/v), and more preferably 1-3% (w/v).
8. The method according to claim 5 or 6, wherein the step (b) is shear mixing using a disk mill, a knife mill, a ball mill, a high-speed pulverizer, and a high-speed mixer, preferably a high-speed mixer.
9. The dry powder pharmaceutical composition of claim 1, 2 or 4 for use in the preparation of a medicament for treating viral diseases, including viral pneumonia and aids, wherein the viral pneumonia is caused by viruses such as influenza virus, parainfluenza virus, cytomegalovirus, adenovirus, rhinovirus, coronavirus, 2019 novel coronavirus, coxsackie, echovirus, herpes simplex, varicella-zoster, rubella, measles and the like.
10. Use according to claim 9, characterized in that the medicament can be a dry powder inhalation formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010090402.0A CN111202722A (en) | 2020-02-13 | 2020-02-13 | Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010090402.0A CN111202722A (en) | 2020-02-13 | 2020-02-13 | Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111202722A true CN111202722A (en) | 2020-05-29 |
Family
ID=70780927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010090402.0A Pending CN111202722A (en) | 2020-02-13 | 2020-02-13 | Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111202722A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112206225A (en) * | 2020-07-16 | 2021-01-12 | 郑鉴忠 | Production method of anti-new coronavirus western medicine with monarch, minister, assistant and guide compatibility |
| WO2021212183A1 (en) * | 2020-04-24 | 2021-10-28 | Centre For Digestive Diseases Pty Limited | Products of manufacture and methods for treating, ameliorating or preventing microbial infections |
| WO2022029604A1 (en) | 2020-08-07 | 2022-02-10 | Council For Scientific And Industrial Research | Microemulsion drug delivery system for treatment of acute respiratory distress syndrome |
| CN114053226A (en) * | 2021-11-18 | 2022-02-18 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof |
| CN114209651A (en) * | 2021-11-18 | 2022-03-22 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof |
| WO2023075714A1 (en) * | 2021-10-25 | 2023-05-04 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder compositions comprising anti-viral agents |
| WO2023177367A1 (en) * | 2022-03-18 | 2023-09-21 | Pulmocures Ilac Egitim Danismanlik A.S. | Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009050217A2 (en) * | 2007-10-15 | 2009-04-23 | Laboratoires Smb | Improved pharmaceutical dry powder compositions for inhalation |
| US20100310660A1 (en) * | 2009-06-08 | 2010-12-09 | Taipei Medical University | Dry powder microparticles for pulmonary delivery |
| US20140212501A1 (en) * | 2011-09-09 | 2014-07-31 | The University Of Liverpool | Compositions of lopinavir |
| US20140220141A1 (en) * | 2011-09-09 | 2014-08-07 | The University Of Liverpool | Compositions of lopinavir and ritonavir |
| US20140294969A1 (en) * | 2011-08-01 | 2014-10-02 | Monash University | Method and formulation for inhalation |
| US20160235749A1 (en) * | 2015-02-12 | 2016-08-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Micro-particulated nanocapsules containing lopinavir with enhanced oral bioavailability and efficacy |
-
2020
- 2020-02-13 CN CN202010090402.0A patent/CN111202722A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009050217A2 (en) * | 2007-10-15 | 2009-04-23 | Laboratoires Smb | Improved pharmaceutical dry powder compositions for inhalation |
| US20100310660A1 (en) * | 2009-06-08 | 2010-12-09 | Taipei Medical University | Dry powder microparticles for pulmonary delivery |
| US20140294969A1 (en) * | 2011-08-01 | 2014-10-02 | Monash University | Method and formulation for inhalation |
| US20140212501A1 (en) * | 2011-09-09 | 2014-07-31 | The University Of Liverpool | Compositions of lopinavir |
| US20140220141A1 (en) * | 2011-09-09 | 2014-08-07 | The University Of Liverpool | Compositions of lopinavir and ritonavir |
| US20160235749A1 (en) * | 2015-02-12 | 2016-08-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Micro-particulated nanocapsules containing lopinavir with enhanced oral bioavailability and efficacy |
Non-Patent Citations (1)
| Title |
|---|
| 国家卫生健康委员会办公厅等: "新型冠状病毒感染的肺炎诊疗方案（试行第三版）", 《天津中医药》, vol. 37, no. 1, pages 1 - 3 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021212183A1 (en) * | 2020-04-24 | 2021-10-28 | Centre For Digestive Diseases Pty Limited | Products of manufacture and methods for treating, ameliorating or preventing microbial infections |
| CN112206225A (en) * | 2020-07-16 | 2021-01-12 | 郑鉴忠 | Production method of anti-new coronavirus western medicine with monarch, minister, assistant and guide compatibility |
| WO2022029604A1 (en) | 2020-08-07 | 2022-02-10 | Council For Scientific And Industrial Research | Microemulsion drug delivery system for treatment of acute respiratory distress syndrome |
| WO2023075714A1 (en) * | 2021-10-25 | 2023-05-04 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder compositions comprising anti-viral agents |
| CN114053226A (en) * | 2021-11-18 | 2022-02-18 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof |
| CN114209651A (en) * | 2021-11-18 | 2022-03-22 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof |
| WO2023177367A1 (en) * | 2022-03-18 | 2023-09-21 | Pulmocures Ilac Egitim Danismanlik A.S. | Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111202722A (en) | Lopinavir inhalation dry powder pharmaceutical composition and preparation method thereof | |
| US20220152145A1 (en) | Method and formulation for inhalation | |
| EP2756840B1 (en) | Pharmaceutical composition for inhalation | |
| US9539211B2 (en) | Ultra low density pulmonary powders | |
| AP1374A (en) | Aerosolizable particles resistant to hygroscopic growth. | |
| CN111202724A (en) | Arbidol inhalation dry powder pharmaceutical composition and preparation method thereof | |
| CN105101955B (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| KR20010101138A (en) | Improvements in or relating to powders | |
| EP1036562A1 (en) | Soft-pellet drug and process for the preparation thereof | |
| JP2015519394A (en) | Dry powder for inhalation preparation containing salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for producing the same | |
| CN111265499B (en) | Lopinavir inhalation aerosol and preparation method thereof | |
| US10517828B2 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| US20080292713A1 (en) | Respirable Powders | |
| JP2020011952A (en) | Ambroxol dry powder for inhalation use with bronchial targets | |
| US11304937B2 (en) | Medicinal composition for inhalation | |
| CN104398497B (en) | Itraconazole inhalation powder spray and preparation method thereof | |
| EP1169065B1 (en) | Methacoline or histamine formulations for detecting asthma | |
| CN111202723A (en) | Darunavir inhalation dry powder pharmaceutical composition and preparation method thereof | |
| CN111110634A (en) | Chloroquine phosphate inhalation aerosol and preparation method thereof | |
| CN106551919B (en) | Novel inhalation formulations | |
| RU2823554C1 (en) | Novel carrier particles for dry powder inhalation formulations | |
| JP2022139708A (en) | Dry powder pharmaceutical composition for inhalation | |
| JP2009509980A (en) | Aerosol powder formulation containing sieved lactose | |
| MXPA00005270A (en) | Soft-pellet drug and process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 211100 building 7, life science and Technology Innovation Park, 568 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Applicant after: Jiangsu ailikang Pharmaceutical Technology Co.,Ltd. Address before: 211100 building 7, life science and Technology Innovation Park, 568 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Applicant before: JIANGSU ALICORN PHARMACEUTICAL Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200529 |